Vojtech Melenovsky1,2, Mads J Andersen1,3, Krystof Andress2, Yogesh N Reddy1, Barry A Borlaug1. 1. Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA. 2. Department of Cardiology, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic. 3. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Abstract
AIMS: The goal of the study was to examine the prognostic impact, haemodynamic and clinical features associated with lung congestion in patients with chronic heart failure (HF). METHODS AND RESULTS: HF patients (n = 186) and HF-free controls (n = 21) underwent right heart catheterization, echocardiography, pulmonary function testing and chest radiography that was blindly scored for the presence and severity of lung oedema. Lung congestion correlated directly with pulmonary vascular resistance (PVR, P = 0.004) and inversely with pulmonary artery (PA) compliance (P < 0.001) and the diffusion limit for carbon monoxide (DLCO , P = 0.009). Compared with dry lung HF, wet lung HF patients (congestion score > median) had 25% lower PA compliance and 25-35% higher PVR, transpulmonary gradients and PA pressures (40 vs. 32 mmHg, P < 0.001) despite marginally higher PA wedge pressure (PAWP; 22 vs. 19 mmHg, P = 0.002). Wet lung HF patients displayed more right ventricular (RV) dilatation and dysfunction, more restrictive ventilation and greater reduction of DLCO . The strongest correlates of lung congestion were NT-proBNP, haemoglobin, albumin, and glomerular filtration, all surpassing PAWP. After a median of 333 days (interquartile range 80-875), 59 patients (32%) died. Lung congestion was associated with reduced survival (P < 0.0001), even after adjusting for PAWP, NT-proBNP, anaemia, CAD and renal dysfunction. CONCLUSION: Interstitial lung oedema is associated with pulmonary vascular disease, RV overload and dysfunction and increased mortality in HF. These data reinforce the importance of aggressive decongestion in HF and suggest that novel agents aimed at reducing lung water may help to deter progression of pulmonary vascular disease and biventricular HF.
AIMS: The goal of the study was to examine the prognostic impact, haemodynamic and clinical features associated with lung congestion in patients with chronic heart failure (HF). METHODS AND RESULTS: HF patients (n = 186) and HF-free controls (n = 21) underwent right heart catheterization, echocardiography, pulmonary function testing and chest radiography that was blindly scored for the presence and severity of lung oedema. Lung congestion correlated directly with pulmonary vascular resistance (PVR, P = 0.004) and inversely with pulmonary artery (PA) compliance (P < 0.001) and the diffusion limit for carbon monoxide (DLCO , P = 0.009). Compared with dry lung HF, wet lung HFpatients (congestion score > median) had 25% lower PA compliance and 25-35% higher PVR, transpulmonary gradients and PA pressures (40 vs. 32 mmHg, P < 0.001) despite marginally higher PA wedge pressure (PAWP; 22 vs. 19 mmHg, P = 0.002). Wet lung HFpatients displayed more right ventricular (RV) dilatation and dysfunction, more restrictive ventilation and greater reduction of DLCO . The strongest correlates of lung congestion were NT-proBNP, haemoglobin, albumin, and glomerular filtration, all surpassing PAWP. After a median of 333 days (interquartile range 80-875), 59 patients (32%) died. Lung congestion was associated with reduced survival (P < 0.0001), even after adjusting for PAWP, NT-proBNP, anaemia, CAD and renal dysfunction. CONCLUSION: Interstitial lung oedema is associated with pulmonary vascular disease, RV overload and dysfunction and increased mortality in HF. These data reinforce the importance of aggressive decongestion in HF and suggest that novel agents aimed at reducing lung water may help to deter progression of pulmonary vascular disease and biventricular HF.
Authors: Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Yogesh N V Reddy; Masaru Obokata; Katlyn E Koepp; Alexander C Egbe; Brandon Wiley; Barry A Borlaug Journal: Circ Res Date: 2019-01-18 Impact factor: 17.367
Authors: Masaru Obokata; Thomas P Olson; Yogesh N V Reddy; Vojtech Melenovsky; Garvan C Kane; Barry A Borlaug Journal: Eur Heart J Date: 2018-08-07 Impact factor: 29.983
Authors: Elke Platz; Allison A Merz; Pardeep S Jhund; Ali Vazir; Ross Campbell; John J McMurray Journal: Eur J Heart Fail Date: 2017-05-30 Impact factor: 15.534
Authors: Ernesto Di Cesare; Scipione Carerj; Anna Palmisano; Maria Ludovica Carerj; Federica Catapano; Davide Vignale; Annamaria Di Cesare; Gianluca Milanese; Nicola Sverzellati; Marco Francone; Antonio Esposito Journal: Radiol Med Date: 2020-07-16 Impact factor: 3.469
Authors: Ahmed U Fayyaz; William D Edwards; Joseph J Maleszewski; Ewa A Konik; Hilary M DuBrock; Barry A Borlaug; Robert P Frantz; Sarah M Jenkins; Margaret M Redfield Journal: Circulation Date: 2017-12-15 Impact factor: 29.690